Interactions between comorbidities: diabetes and kidney disease together change the risk calculation for hypoglycemia and for medication clearance. They are not independent variables.
26 likes 23mo
Topic summary
Gallbladder disease risk with rapid weight loss
This is a generated summary. It shows the 9 most-liked posts from a topic of 64, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
33 likes 22mo
Hepatic steatosis and MASH: a phase 2 trial in semaglutide for steatohepatitis showed resolution was more frequent on treatment. Histological resolution is a surrogate for long-term clinical outcomes like cirrhosis.
33 likes 21mo
resistance_first, post #10: On post #6 — agreed on the reasoning, with one qualification. Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and cardiovascular benefit evidence is separate from the glycaemic benefit evidence. Go to post
Picking up post #26: that is the part I would want checked first.
Multiple comorbidities: a person with diabetes, kidney disease, and cardiovascular disease is outside the studied populations in most trials. Extrapolating to that person requires reasoning from the individual component trials and mechanisms.
PCOS and metabolic overlap: polycystic ovary syndrome has metabolic overlap with obesity and insulin resistance. Data on compounds in this class in PCOS specifically is thin; most discussion is by mechanism.
31 likes 20mo
h.amankwah, post #40: post #39 answers the question as asked. The question underneath it is different. Hepatic steatosis and MASH: a phase 2 trial in semaglutide for steatohepatitis showed resolution was more frequent on treatment. Histological resolution is a surrogate for long-term clinical outcomes like cirrhosis. Go to post
Bariatric surgery history: altered anatomy after surgery affects absorption. That matters for oral medications and for reconstituted solutions. Discussing specific medications and doses with a clinician familiar with bariatric surgery is prudent.
Read the full topic (64 posts)
This topic was referenced in
- Cardiovascular risk: reading the outcome trials as a setClinical › Comorbidities · 4 replies
- Heart failure with preserved ejection fraction: symptom endpointsClinical › Comorbidities · 23 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Gastro-oesophageal reflux: improving or worsening?
The question in the title: Gastro-oesophageal reflux: improving or worsening? I will give what I have already checked below so nobody repeats it. Asking about a population rather than about a person. The…
|
+54 | 58 | 8.2k | 1mo |
|
Obstructive sleep apnoea and a hard endpoint in this class
On the subject in the title: Obstructive sleep apnoea and a hard endpoint in this class Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in…
|
+120 | 129 | 1.8k | 13mo |
|
About the Comorbidities category
Type 2 diabetes, hepatic steatosis, sleep apnoea, cardiovascular and renal disease. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 16k | 12h | |
|
Osteoarthritis and mechanical versus metabolic improvement
Osteoarthritis and mechanical versus metabolic improvement Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…
|
+2 | 6 | 30k | 12h |
|
Heart failure with preserved ejection fraction: symptom endpoints
Heart failure with preserved ejection fraction: symptom endpoints — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published…
|
+19 | 23 | 311 | 12d |
Related topics — sharing the tags obstructive sleep apnoea, type 2 diabetes, chronic kidney disease
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Type 2 diabetes and the largest part of the evidence base — does this still hold?
Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather…
|
+17 | 22 | 4.5k | 1d |
|
Obstructive sleep apnoea and a hard endpoint in this class
On the subject in the title: Obstructive sleep apnoea and a hard endpoint in this class Working notes rather than a conclusion. Asking about a population rather than about a person. The published trials in…
|
+120 | 129 | 1.8k | 13mo |
|
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…
|
+112 | 119 | 3.3k | 11mo |
|
Revisiting: Heart failure with preserved ejection fraction: symptom endpoints
On the subject in the title: Revisiting: Heart failure with preserved ejection fraction: symptom endpoints Working notes rather than a conclusion. General question, not a request for advice about my own care…
|
+4 | 8 | 43k | 17mo |
|
About the Sleep category
Sleep quality, apnoea, and the bidirectional relationship with metabolic health. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and…
|
+1 | 5 | 92 | 4mo |